Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review - PubMed
3 days ago
- #alopecia areata
- #JAK inhibitors
- #ivarmacitinib
- Alopecia areata (AA) is a chronic, immune-mediated hair loss disorder linked to the JAK-STAT signaling pathway.
- JAK inhibitors are cornerstone treatments for severe AA, but responses vary.
- Ivarmacitinib, a novel and highly selective JAK1 inhibitor, recently approved for AA in China, showed significant improvement in a patient with suboptimal response to tofacitinib.
- The case suggests ivarmacitinib as a viable alternative for tofacitinib-refractory AA, possibly due to higher JAK1 selectivity.
- Further studies are needed to define ivarmacitinib's optimal position in AA treatment and elucidate mechanisms for personalized therapy.